The Chinese government continues to invest in reforming its 
healthcare ecosystem. A key element of these reforms is the essential 
drug list (EDL), intended to reduce drug costs. The new EDL 
environment will create challenges and opportunities for 
pharmaceutical companies, pharmaceutical distributors and hospitals, 
as well as trigger changes in how they operate and 
compete.  Integration and collaboration supported by information 
sharing will be required across four areas: new  differentiated 
services development, operational excellence, sales effectiveness and 
supply chain optimization.

http://bit.ly/aLxDUv (IBM)


"People Who experience mood swings, fear, voices and visions"